Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -11.63% 19.00 319,794 11:54:22
Bid Price Offer Price High Price Low Price Open Price
18.00 20.00 21.50 19.00 21.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 22
Last Trade Time Trade Type Trade Size Trade Price Currency
15:09:56 O 50,000 19.00 GBX

Polarean Imaging (POLX) Latest News

More Polarean Imaging News
Polarean Imaging Takeover Rumours

Polarean Imaging (POLX) Discussions and Chat

Polarean Imaging Forums and Chat

Date Time Title Posts
25/3/202012:39Polarean Imaging PLC308

Add a New Thread

Polarean Imaging (POLX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-03-30 15:09:5619.0050,0009,500.00O
2020-03-30 14:04:3519.5051,2829,999.99O
2020-03-30 13:45:4418.2625,0004,565.00O
2020-03-30 11:30:5719.507,1791,399.90O
2020-03-30 11:01:2218.10900162.90O
View all Polarean Imaging trades in real-time

Polarean Imaging (POLX) Top Chat Posts

DateSubject
30/3/2020
09:20
Polarean Imaging Daily Update: Polarean Imaging Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker POLX. The last closing price for Polarean Imaging was 21.50p.
Polarean Imaging Plc has a 4 week average price of 17.45p and a 12 week average price of 17.45p.
The 1 year high share price is 39.50p while the 1 year low share price is currently 13.50p.
There are currently 114,438,600 shares in issue and the average daily traded volume is 100,197 shares. The market capitalisation of Polarean Imaging Plc is £21,743,334.
15/3/2020
16:58
diversification: New jurisdictionsBracco Imaging generated 38% of their 2018 revenue from Europe and in my opinion would now be a leading contender as a strategic partner. Distributing our IP within Europe following their strategic investment, and given that this would compliment their current product mix makes this highly probable.News flow is likely to continue given the pre-NDA, increase in IP and pre-commercialization steps. CREO is a good example of likely news flow activity.My expectation is that with uncertainties around funding up until FDA approval now gone, we should see a sustainable re-rating of the share price over time and leading up to approval.
03/2/2020
13:01
diversification: So around 240k shares traded and roughly £50k worth of shares sold from what I can make out and the share price is down 6.5%. Mm games and a dirt cheap share to continue taking advantage of.
29/1/2020
19:43
diversification: Share register rebalanced Fantastic results today, and while these results were expected the main news today is that the market seems to of filtered out some of the traders and profit takers which was really good to see. Too much hot money is not necessarily a good thing, a sustainable long term uptrend is far more appealing. Funding Recent director purchases would have provided a base to the current share price, as for Allis to have continued to build a sizable position in the company knowing the companies forward cash position, surely if a sizable placing was planned he could of just participated in that. It is also worth noting that the CEO has insisted in the past that the company cash burn is very little following the expensive phase III trial which should see the company through to approval. Strategic partnerships Today’s read out is a key milestone for the company to enable it to enter strategic partnerships which in itself would resolve any funding concerns. NDA Monday this week I contacted investor relations to help clarify priority FDA reviews and Hatch Waxman. I am waiting a response as it was implied that Richard was very busy this week and it may take a couple of days to reply. Conclusion (in my opinion) Imo something significant is being worked on in the background that has led the company directors to build on their own position in the free market. Allis will be only to aware of the potential of this company following the sale of Blue Earth D which means that he has unfinished business in building a more significant stake in POLX. Relatively low forward cash burn enables the company to go into the next 18 months with a relatively clear path to market which can give current shareholders certainty about forward dilution. To consider a small raise would not be the end of the world but I think the company will naturally clarify its forward position in the not to distant future. NDA application, strategic partnerships and further sale of goods for research purposes (funding through grants, which enables the company to have a clear view of forward order book), will all contribute towards future funding and will be significant share price catalysts as it’s the unknowns that the market will struggle to price in. Between now and FDA approval, the free float will continue to shrink which will intensify and future forward moves. I have seen many stocks that have seen a continuation of an upwards trend in anticipation of FDA approval over a longer period of time (STX) and also over a shorter period of time just before FDA results. I see no reason for this to be any different, other than the fact that this is a computer v computer which will help increase the probability of success. None of which is currently priced in, but prior to what could/should be FDA approval and commercialization would see a market cap in excess of £100m which in itself is a share price of 87p or a 170% increase on today’s price which would be more than conservative knowing the commercial numbers, even for a pre-approved application at this stage of its lifecycle.
16/1/2020
12:17
loglorry1: This has all the hallmarks of the share price trend of STX from 2019. I honestly can’t believe how under the radar this stock is and it’s one to tuck away. Yes and STX is c£200m market cap. That would take POLX to about 200p/share.
16/1/2020
10:49
diversification: This has all the hallmarks of the share price trend of STX from 2019. I honestly can't believe how under the radar this stock is and it's one to tuck away. The razor/blade analogy is very appropriate for this stock as it grows it's revenue streams at 100% ownership rather than diluting ownership of revenue by licensing out to big Pharma. While this maybe likely for China. It's potential as an aim investment is as good as I have seen for a very long time. I only wish I had found it sooner.
10/12/2019
15:25
rhatton: Thanks for your response, I was thinking about it in terms of comparing this to what kind of share price reaction they might be on positive phase 3 results. That as it differs from a drug in terms of an actual cure or maybe a far better treatment option, it might be less of a rise than some expect
04/10/2019
13:25
anakin54321: Good spot McFly. Yep - sounds like commercial (as opposed to research which he states are going at least to plan) sales start of 2021. He does reference a parallel application giving 5 yrs market exclusivity that pushes the usual 10 month approval process to 12. Any investor in this for the long haul will take that I reckon. A good interview though, with clear references to the massive market size in USA/Europe/Asia. I think we need to remember that the share price won't wait till sales start and should rise appreciably on a successful phase 3 outcome (stated as before year end) and the expectation of sales and profits thereafter.
24/9/2019
08:40
slicethepie: Update reads well. Any views on our chairman ? His other entity, AMP, has been a disaster for shareholders. The overhang / recent selling by AMP has depressed our share price and needs sorting, seems to be a conflict of interests.
28/8/2019
10:32
kj kelley: Amphion's may not have the luxury of selling into the news. Loan favility is due to be repaid on 30th September 2019. It has pledged it's Polarean shareholding against this debt. It is trying to refinance or extend this debt. As the debt is effectively to allow Amphion to speculate on the price of POLX shares, I would be surprised if lenders would provide more funds to Amphion, especially in the current financial climate. The debt outstanding is $2.8m against which POLX shares are pledged. The value of the POLX shares was $5.3m on 9th August and is now worth $4.8m. Of this $4.8m the lenders are entitled to 15% of the aprreciation above 18p share price of POLX, whcih is around $0.2m currently. So we might see the lender acquiring POLX shares in repayment of the debt and these shares being sold. Amphion has a market cap of £0.3m and the company's total debt is $30.3m. It's accounts have not been published as the auditors are continuing work in relation to the going concern status of the company. It seems that Amphion is very close to being declared bust. If so this will create a substantial overhang in Polarean's shares. This years placing at 18p showed that there was demand for the shares at that price. Althought market conditions have chnaged since then.
Polarean Imaging share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
POLX
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200330 23:58:44